The FDA assessed the security and efficiency of atidarsagene autotemcel determined by info from 37 youngsters who received atidarsagene autotemcel in two one-arm, open up-label clinical trials As well as in an expanded entry method.[seven] Young children who acquired treatment method with atidarsagene autotemcel have been when compared to untreated